咪达那新u200c片(Uritos)的注意事项和药物相互作用

Uritos is a new type of selective M3/M1 receptor antagonist developed by Japan's Kyorin Pharmaceuticals. It was approved for marketing in Japan in 2007.

Important contraindications and warnings of Midanacin Tablets (Uritos)

1. People with absolute contraindications

(1) Patients with urinary retention: the anticholinergic effect of Uritos will inhibit bladder contraction and aggravate dysuria.

(2) Patients with gastrointestinal obstruction: including pyloric, duodenal or intestinal obstruction, and patients with paralytic intestinal obstruction. Medications can inhibit smooth muscle motility in the gastrointestinal tract and worsen symptoms.

(3) Patients with angle-closure glaucoma: Drugs may cause an increase in intraocular pressure and induce or aggravate glaucoma.

(4) Patients with myasthenia gravis: It may aggravate myasthenic symptoms.

(5) Patients with severe heart disease: There are reports that it may cause arrhythmia (such as premature contractions, QT interval prolongation) and aggravate heart disease.

(6) Those who are allergic to any ingredients of this product.

2. Evaluation and differential diagnosis before using Midanacin Tablets (Uritos)

Before using Midanacin Tablets, the diagnosis must be confirmed through detailed consultation and necessary examinations (such as urine routine) to exclude other diseases with similar symptoms.

The pictures come from public channels (such as the official website of the FDA, the official website of the original drug manufacturer, etc.) and are for reference only.

Precautions for use of Midanacin Tablets (Uritos) in special groups

1. People with liver and kidney insufficiency

(1) Hepatic impairment: This product is mainly metabolized in the liver. Patients with moderate or above liver impairment should use low doses (0.1 mg once, twice a day), because decreased liver function may lead to increased drug exposure and are more likely to cause side effects. People with mild liver damage also need to be cautious.

(2) Renal damage: This product is partially excreted by the kidneys. Patients with severe renal impairment should use low doses (0.1 mg twice a day). People with mild to moderate renal impairment should also be aware of the risk of delayed drug excretion.

2. Pregnant and lactating women

(1) Pregnant women: Animal experiments show that the drug can cross the placenta. Unless the potential benefits outweigh the risks, it is not recommended for pregnant women to use.

(2) Lactating women: Animal experiments show that the drug can be excreted through milk. The necessity of treatment and the benefits of breastfeeding should be weighed to decide whether to stop breastfeeding or stop taking the drug.

3. Patients with other specific diseases

(1) Patients with cognitive dysfunction or dementia: Patients who may aggravate the symptoms of cognitive impairment and cannot clearly perceive improvement in OAB symptoms should not use it.

(2) Patients with Parkinson's disease or cerebrovascular accident: symptoms may be aggravated or psychoneurological symptoms may occur.

(3) Patients with ulcerative colitis: There is a risk of toxic megacolon.

(4) Patients with hyperthyroidism: Symptoms of sympathetic nervous excitement such as tachycardia may be aggravated due to anticholinergic effects.

Drug interactions of Midanacin Tablets (Uritos)

1. Metabolism-related interactions

Imidanacin is mainly metabolized by the CYP3A4 enzyme in the liver. Combining it with a strong CYP3A4 inhibitor will significantly increase the blood concentration and increase the risk of adverse reactions.

Interacting drugs: itraconazole, clarithromycin, erythromycin, etc.

Recommendation: Caution should be exercised when combining medications and adverse reactions should be closely monitored.

2. Pharmacodynamic-related interactions

Combined use with other drugs with anticholinergic effects will produce additive effects, increasing the incidence and severity of anticholinergic side effects.

Interacting drugs: tricyclic antidepressants (such as amitriptyline), phenothiazines, monoamine oxidase inhibitors, etc.

Clinical impact: The risk of exacerbation of symptoms such as dry mouth, constipation, and difficulty urinating is significantly increased.

Recommendation: Combined use should be avoided. If use is necessary, the patient's status needs to be closely monitored.